-+ 0.00%
-+ 0.00%
-+ 0.00%
Puma Biotechnology Sees Q2 Sales $52.000M-$55.000M vs $52.000M Est
Share
Listen to the news

Second Quarter and Full Year 2026 Financial Outlook

 

Second Quarter

2026

New

Full Year 2026

Prior

Full Year 2026

Net Product Revenue $50–$52 million $202-206 million $194–$198 million
Royalty Revenue $2–$3 million $20–$23 million $20–$23 million
License Revenue $0 $0 $0
Total Revenue $52–$55 million $222-$229 million $214–$221 million
Net Income* $2–$4 million $16-$19 million $10–$13 million
Gross to Net Adjustment 27%–28% 26.5%-27.5% 27.5%–28.5%
       
*The outlook above does not include any potential adjustments for tax valuation allowance
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending